{"id":"NCT02638259","sponsor":"Sandoz","briefTitle":"Comparative Efficacy and Safety Study of GP2015 and Enbrel® in Patients With Rheumatoid Arthritis","officialTitle":"A Randomized, Double-blind, Parallel-group Phase III Study to Demonstrate Equivalent Efficacy and to Compare Safety & Immunogenicity of GP2015 and Enbrel® (EU Authorized) in Patients With Moderate to Severe, Active Rheumatoid Arthritis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-02-21","primaryCompletion":"2016-12-29","completion":"2017-06-12","firstPosted":"2015-12-23","resultsPosted":"2018-02-23","lastUpdate":"2018-09-19"},"enrollment":376,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"DRUG","name":"GP2015","otherNames":[]}],"arms":[{"label":"50mg GP2015","type":"EXPERIMENTAL"},{"label":"50mg EU-authorized Enbrel","type":"ACTIVE_COMPARATOR"}],"summary":"Demonstrate equivalent efficacy of GP2015 and EU-authorized Enbrel in patients with moderate to severe, active (RA) who had an inadequate response to disease modifying anti-rheumatic drugs (DMARD) including methotrexate (MTX).","primaryOutcome":{"measure":"Safety: Change in DAS28-CRP Score From Baseline to Week 24 in Patients Treated With GP2015 and Patients Treated With Enbrel","timeFrame":"treatment period 1: up to 24 weeks","effectByArm":[{"arm":"50mg GP2015","deltaMin":-2.8,"sd":0.113},{"arm":"50mg EU-authorized Enbrel","deltaMin":-2.73,"sd":0.117}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":3},"locations":{"siteCount":92,"countries":["United States","Bulgaria","Czechia","Estonia","Germany","Hungary","Italy","Latvia","Lithuania","Mexico","Poland","Russia","Serbia","Slovakia","Spain","United Kingdom"]},"refs":{"pmids":["40279006","31138316","30487998"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":186},"commonTop":["Injection site reaction","Nasopharyngitis","Upper respiratory tract infection","Urinary tract infection","Alanine aminotransferase increased"]}}